Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Talk outline
3. Viruses as pathogens and tools
4. Viruses as vaccines
5. Viruses as vaccines - results
6. The frontier: from viruses to oncolytics
7. Oncolytic virotherapy - definition
8. The promise of oncolytic virotherapy
9. Targeting viruses to tumors: layers of specificity
10. DNA viruses in cancer clinical trials
11. RNA viruses in cancer clinical trials
12. Measles as an oncolytic virus
13. Regression of lymphoma after measles infection
14. Pre-clinical trials with oncolytic measles viruses
15. Biology of measles virus
16. Measles and non-segmented negative RNA viruses
17. Measles virus particles
18. Expression of reproter genes in measles virus
19. Measles virus - genome and particle activation
20. Matrix metalloproteinases (MMP)
21. In situ activation of viruses by MMPs
22. MV fusion protein activation and inactivation
23. Conferring MMP-2 specific activation
24. Recovery of MMP-activated MV
25. MV-MMP-A: fusion of MMP-secreting cells
26. MV-MMP-A1: safety and efficacy
27. Summary - first layer of targeting
28. Tropism retargeting - layer 2, cell entry
29. The strategy: modification of attachment protein H
30. Retargeting cell entry (1)
31. Measles virus receptor SLAM/CD46 based tests
32. Mutants supporting SLAM/CD46 dependent fusion
33. SLAM/CD46-dependent fusion important residues
34. Entry through targeted receptor
35. Retargeting cell entry (2)
36. Retargeting tropism: layer 3 and layer 4
37. Retargeting tropism: spread (1)
38. Oncolytic MV have a mutated Zn-binding domain
39. Properties of the mutated V protein
40. Conservative modification of V protein
41. Retargeting tropism: spread (2)
42. Interaction of V protein with mda5 and STAT2
43. Interaction of V and P with STAT1
44. Recombinant measles virus with desired mutations
45. Retargeting tropism: spread (3)
46. Topical clinical trials
47. Oncolytic viruses as cancer therapeutics
48. Head and neck carcinoma: approved regimen
49. Ongoing trials: prostate cancer
50. Ongoing trials: glioma
51. Ongoing trials: advanced liver tumors
52. Ongoing trials: superficial tumors
53. Ovarian carcinoma, multiple myeloma
54. Summary of clinical trials
55. Improving efficacy of oncolytic virotherapy activity
56. Choosing the ideal oncolytic virus
57. Acknowledgements

Topics Covered

• Viruses: molecular biology and reverse genetics
• Tropism determinants: entry and post-entry levels
• Tropism targeting: protease activation, receptor attachment, transcription/replication, spread
• Cancer clinical trials: recombinant adeno-, herpes, vaccinia and measles viruses

Links

Series:

• Viruses and Viral Diseases

Categories:

• Cancer
• Methods
• Microbiology

Therapeutic Areas:

• Oncology

Talk Citation

Publication History

• Published on October 1, 2007
• Archived on February 28, 2018

Financial Disclosures

• Prof. Roberto Cattaneo has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.